RxDoctor Payments Data

Samir Kassicieh, DO

Family Medicine · Albuquerque, NMNPI 1730254350

Payments from drug & device makers

$1,056in general payments, 2019–2025

Across 47 payments — averaging $22.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$583
  • Nevro Corp.$58
  • Boehringer Ingelheim$56
  • Xeris Pharmaceuticals, Inc.$44
  • AbbVie$44
  • Amarin Pharma, Inc.$40
  • plus $231 from 10 others

What the payments were for

  • Food & beverage$1,056100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,056 in reported general payments places this provider in the 80th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$80,656
Medicare patients
115
Services billed
2,697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide85$86,644
FarxigaDapagliflozin Propanediol106$85,032
QutenzaCapsaicin/Skin Cleanser19$67,337
TrulicityDulaglutide39$50,142
EliquisApixaban51$40,349
JanuviaSitagliptin Phosphate42$33,238
XareltoRivaroxaban12$16,490
Tresiba Flextouch U-200Insulin Degludec12$15,649
Tresiba Flextouch U-100Insulin Degludec24$14,718
Spiriva HandihalerTiotropium Bromide21$12,036
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog33$10,385
InvokanaCanagliflozin15$9,917
Albuterol Sulfate HfaAlbuterol Sulfate239$9,411
Lantus SolostarInsulin Glargine,hum.Rec.Anlog54$8,903
Levemir FlexpenInsulin Detemir27$8,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$35$86,64485 claims
PfizerEliquis$11$40,34951 claims
Johnson & JohnsonXarelto, Invokana$25$26,40727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →